4162.Two
4162.TWO is a biotechnology company engaged in healthcare diagnostics, generating revenue primarily through the development and sale of diagnostic products and services.
Business. 4162.TWO is a biotechnology company engaged in healthcare diagnostics, generating revenue primarily through the development and sale of diagnostic products and services.
Analyst recommendations
1 analysts · consensus HoldAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
4162.TWO is a biotechnology company engaged in healthcare diagnostics, generating revenue primarily through the development and sale of diagnostic products and services.
The company maintains a strong liquidity position, with a current ratio of 27.17, indicating a significant excess of current assets over current liabilities. Its cash and equivalents amount to 1,521,060,000 TWD, which is a substantial portion of its total assets of 5,147,512,000 TWD. The company's debt-to-equity ratio is 0.01, suggesting a very low reliance on debt financing and a strong equity base. This capital structure supports a low liquidity risk profile, as confirmed by the risk assessment.
In terms of profitability, the company's return on equity (ROE) is 7.87%, and its return on assets (ROA) is 7.53%. These figures are strong and suggest that the company is effectively utilizing its equity and assets to generate returns. The operating income of 425,461,000 TWD and net income of 387,641,000 TWD further support the company's profitability. The gross profit margin is 94.3%, indicating that the company is able to maintain high margins on its products and services.
The company's revenue is concentrated in a single business segment, as no segmental breakdown is provided in the available data. There is no information on geographic exposure, but the company's operations are likely centered in its home market. The lack of segmental or geographic diversification may pose a concentration risk, although the risk assessment does not indicate a high level of concern.
The company's growth trajectory is supported by its strong operating cash flow of 1,726,850,000 TWD and a revenue of 911,416,000 TWD. However, the free cash flow is negative at -464,511,000 TWD, which may indicate that the company is reinvesting heavily in its operations or facing high capital expenditures. The capital expenditure of -280,000 TWD is relatively low, suggesting that the company is not currently making large investments in new assets.
The risk assessment indicates a low level of dilution risk, with no immediate filing-based liquidity or dilution flags detected. The company's shares outstanding are the same for both basic and diluted shares, suggesting that there is no significant potential for dilution from stock options or convertible securities. The low dilution risk is further supported by the absence of any recent issuance or shelf registration activity in the available data.
Recent events, as reflected in the financial data, show a stable performance with a mean recommendation of 3.00 from analysts, indicating a neutral stance. The last actual EPS was 2.69 TWD, slightly below the mean EPS estimate of 2.76 TWD, suggesting that the company is meeting but not exceeding analyst expectations. There are no strong buy or buy recommendations, with only one hold recommendation, indicating a cautious outlook from the analyst community.
- The company has a strong liquidity position with a high current ratio and significant cash reserves.
- The company's profitability is strong, with high ROE and ROA, and a high gross profit margin.
- The company's revenue is concentrated in a single segment, which may pose a concentration risk.
- The company's free cash flow is negative, indicating potential reinvestment or high operational costs.
- The company has a low dilution risk, with no immediate filing-based liquidity or dilution flags.
- Analysts have a neutral outlook on the company, with no strong buy or buy recommendations.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | 2,76 |
| Revenue | —no estimate | —no estimate | 944,0M TWD |
| Operating income | —no estimate | —no estimate | 503,0M TWD |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- 4162.TWO Market data — financials · 2026-05-26
- PharmaEngine Inc Market data — analyst estimates · 2026-05-26